07/15/2020 12:00 AM EDT
Source: National Institutes of Health (NIH). Published: 7/15/2020. The speaker in this one-hour lecture describes his work on the combinatorial development of nanoparticulate, intracellular delivery systems for RNA therapy and gene editing. Libraries of degradable polymers and lipid-like materials have been synthesized, formulated, and screened for their ability to deliver macromolecular payloads inside of cells. These nanoformulations facilitate in vivo delivery, enabling gene suppression with small-interfering RNA, gene expression with messenger RNA, or permanent genetic editing using the CRISPR/Cas9 system. (Video or Multimedia)
07/15/2020 12:00 AM EDT
Source: UK Collaborative on Development Research (UKCDR). Published: 7/15/2020. This 71-page report aims to identify the current global COVID-19 research priorities for this and future pandemics of COVID-19 or new pathogens, and calls for the use of research evidence on the optimal implementation of public health interventions for COVID-19 in varied global settings. (PDF)
07/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/13/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Compass Laboratory Services SARS-CoV2 Assay that has been issued an Emergency Use Authorization (EUA) by the FDA. The Compass Laboratory Services SARS-CoV2 Assay is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider or self-collected using a home collection kit specified in the test’s labeling. (PDF)
07/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/13/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the PhoenixDx SARS-CoV-2 Multiplex. The PhoenixDx SARS-CoV-2 Multiplex is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
Fact Sheet for Healthcare Providers: PowerChek 2019-nCoV Real-time PCR Kit – KogeneBiotech Co., Ltd.
07/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/13/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the PowerChek 2019-nCoV Real-time PCR Kit. The PowerChek 2019-nCoV Real-time PCR Kit is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/13/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/13/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Sienna-Clarity COVIBLOCK COVID-19 IgG/IgM Rapid Test Cassette. This test is authorized for the detection of antibodies to SARS-CoV-2 in human serum, plasma (dipotassium EDTA, sodium citrate, sodium heparin) and venous whole blood (dipotassium EDTA, sodium citrate, sodium heparin). (PDF)
07/13/2020 12:00 AM EDT
Source: Stanford University. Published: 7/13/2020. The purpose of this study is to understand the spread of the COVID-19 and the impact on patients with cancer. Specifically, we want to understand how COVID-19 has impacted patient's lives and their cancer care. The objective is to enhance our knowledge of the evolving COVID-19 pandemic among patients with cancer. The data collected in this survey will help to understand how cancer care is being affected for patients with cancer and potential ways to mitigate this impact. Population: Adults Only Length: 74 Questions Time to Complete: 5-10 minutes Mode of Administration: Face-to-face Online (e.g., computer-assisted interview) Pen and Paper Telephone Administered by: Lay Interviewer Professional Interviewer Self Administered Specialist/Doctor/Expert Trained Lay Examiner/Interviewer Language(s): English, Spanish, Vietnamese (PDF)
07/13/2020 12:00 AM EDT
Source: Alliance for Child Protection in Humanitarian Action. Published: 7/13/2020. This 15-page paper is meant to help decision-makers frame a holistic analysis of school closure on the well-being of children and young people, and to consider the safe reopening of schools during the COVID-19 pandemic. It provides a balanced analysis to inform decisions based on holistic child well-being as to when and why to reopen schools. (PDF)
07/11/2020 12:00 AM EDT
Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 7/11/2020. This six-page paper focuses on the issue of stigmatization as a common underlying dynamic, heightened as a result of COVID-19, which is creating and exacerbating risks of violence, coercion, and deliberate deprivation of vulnerable people. (PDF)
07/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/10/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the WANTAI SARS-CoV-2 Ab Rapid Test. The WANTAI SARS-CoV-2 Ab Rapid Test is authorized for the detection of total antibodies to SARS-CoV-2 inhuman serum, plasma (EDTA, lithium heparin, and sodium citrate) and venous whole blood. (PDF)
07/08/2020 12:00 AM EDT
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 7/8/2020. This 12-page document from TRACIE (Technical Resources, Assistance Center, and Information Exchange), updated on July 8, 2020 lists key COVID-19 guidance and resources for hospital administrators, hospital emergency planners, and infection control practitioners in the following topical areas: hospital surge, crisis standards of care, staffing surge and resilience, workforce protection, regulatory relief, equipment supply surge, healthcare recovery and resumption of services during COVID-19, and telemedicine. (PDF)
07/02/2020 12:00 AM EDT
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 7/2/2020. This nine-page document provides recommendations and resources in response to a request for information on palliative care during the COVID-19 pandemic. It includes general considerations related to the delivery of specialized care by providers and teams to individuals with serious illnesses to manage their symptoms, determine their care goals, and coordinate their medical, behavioral health, and social supports. (PDF)
07/01/2020 12:00 AM EDT
Source: University of Oklahoma. Published: 7/2020. This is a tool for conducting observations of risky or preventive COVID-19 related behaviors (e.g., social distancing, mask wearing, PPE, etc.) from a distance. It facilitates the collection of both qualitative and quantitative data. Questions Adapted From: Behavior Inventory - People and Dogs Population: All/Anyone Length: 5 questions with subquestions Time to Complete: 10 minutes Mode of Administration: Pen and Paper Administered by: Trained Lay Examiner/Interviewer Language(s): English (PDF)
07/01/2020 12:00 AM EDT
Source: University of South Alabama. Published: 7/2020. This is a 32-item, eight-dimension, self-report scale that can be administered online or via pencil and paper. The purpose of this scale is to assess perceptions regarding face mask wearing, and it is composed of eight dimensions with four items representing each dimension. The eight dimensions (with example items) are: comfort ("Face masks disrupt my breathing"), efficacy doubts ("Face masks provide few health benefits"), access ("I do not know where to buy a face mask"), compensation ("I stay away from people when I go out"), inconvenience ("I forget to wear a face mask when going out"), appearance ("Face masks look silly"), attention ("Face masks make people seem untrustworthy"), and independence ("I do not like blindly following suggestions"). The scale is administered with the following instructions: "Please indicate the extent to which you disagree to agree with the following statements regarding face masks, which refers to cloth coverings worn on the face typically intended to prevent the spread of disease and illness. Answer each of the following items as if they began with: When I do not wear a face mask in public it is because. . ." The psychometric properties and validity of the scale were strongly supported in a prior study (Howard, 2020). In Study 1, Howard (2020) utilized a qualitative coding approach to create the items based on participants' stated reasons for not wearing face masks. In Study 2, Howard (2020) supported the factor structure of the scale via exploratory factor analysis (EFA), provided evidence of the scale's concurrent validity, and demonstrated that certain dimensions significantly correlated to face mask wearing. In Study 3, Howard (2020) further supported the factor structure of the scale via confirmatory factor analysis (CFA). Together, these cumulative results provide assurance that this scale adequately gauges face mask perceptions in a multidimensional manner. Population: Adult Workers Adults and Teens All/Anyone Cleanup/Disaster Worker Length: 32 Items Time to Complete: 3 Minutes Mode of Administration: Face-to-face Online (e.g., computer-assisted interview) Pen and Paper Telephone Administered by: Lay Interviewer Parent/Teacher Professional Interviewer Self Administered Specialist/Doctor/Expert Trained Lay Examiner/Interviewer Language(s): English (Text)
07/01/2020 12:00 AM EDT
Source: American Academy of Pediatrics (AAP). Published: 7/2020. This web page provides answers to frequently asked questions during the COVID-19 pandemic about family presence policies, which are are critical components of family-centered care for all children and are particularly important for children with special health care needs, including those with disabilities, medical complexity, and serious illness. (Text)
07/01/2020 12:00 AM EDT
Source: Project Hope. Published: 7/2020. This course details how to safely and effectively screen, triage, and treat patients with COVID-19. It is designed for health workers and leadership on the frontlines of the crisis to increase their capacity to respond rapidly and efficiently to the threat of COVID-19, while also protecting their own health. It is provided in collaboration by Project HOPE, DisasterReady, and the Center for Human Rights and Humanitarian Studies at the Watson Institute of Brown University. (Video or Multimedia)
06/30/2020 12:00 AM EDT
Source: Research Data Alliance (RDA). Published: 6/30/2020. This 143-page document aims to clearly define detailed guidelines on data and software sharing under the present COVID-19 circumstances to help stakeholders follow best practices to maximize the efficiency of their work, and to act as a blueprint for future emergencies. (PDF)
05/20/2020 12:00 AM EDT
Source: Yale University. Published: 5/20/2020. This 7-item self-report instrument is intended for individuals who are participating in ongoing clinical research during the coronavirus pandemic. It was developed to quantify changes in psychosocial, functional, and financial factors that may influence clinical research participation and clinical research study outcomes. The domains measured include: (1.) Access to Healthcare, (2.) Social Support, (3.) Finances, (4.) Ability to Meet Basic Needs, (5.) Mental and Emotional Health as well as a participant (subjective) experience of personal and family exposure to coronavirus. It was designed to quickly assess, in a minimally-burdensome manner, the positive and negative aspects of the pandemic on multiple mediating factors that may impact study outcomes. This instrument has a 3-month look back which can be adjusted to fit the study design. The tool is intended to be delivered at multiple time points (baseline and follow-up) to measure changes over time. This instrument was developed by researchers for the Pain Management Collaboratory (PMC) which involves 11 pragmatic trials studying non-pharmacological approaches to pain management (e.g. physical therapy, chiropractic care, meditation) in military personnel and veterans; however, this instrument was written broadly enough to be used with any adult population involved in clinical research. Questions Adapted From: The Phenotype and Outcome Work Group, within the Pain Management Collaboratory Coordinating Center (PMC3), is comprised of representatives from 11 pragmatic pain trials. The PMC3 collected COVID-related questionnaires from public sources, published instruments, and investigators within the Collaboratory. The Work Group members then met to review the resources compiled by PMC3, identified the key domains of interest, selected a question/response structure proposed for use by three PMC trial groups, revised the language within each question item until a consensus was obtained, and drafted the final instrument. This instrument has been approved by the Steering Committee for harmonized use of across PMC trials. Population: Adults Only Length: 7 items Time to complete: <5 minutes Mode of Administration: Online (e.g., computer-assisted interview); Pen and Paper; Telephone Administered by: Self Administered Language: English (PDF)
03/01/2020 12:00 AM EST
Source: U.S. Department of Housing and Urban Development (HUD). Published: 3/2020. This one-page document provides a table for designing local approaches to continuums of care that consider non-congregate approaches to sheltering people who are homeless and are symptomatic or in high risk categories, such as seniors or people with chronic illness, during the COVID-19 pandemic. (PDF)
03/01/2020 12:00 AM EST
Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 3/2020. The purpose of this 13-page document, co-published with UNICEF, the World Health Organization, and International Federation of the Red Cross, is to provide clear and actionable guidance for safe operations through the prevention, early detection, and control of COVID-19 in schools and other educational facilities. (PDF)
No hay comentarios:
Publicar un comentario